Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
DSGN 11.07.2024
Drug:DT-216P2 DT-216P2
Drug:DT-168 DT-168
Diseases:Friedreich Ataxia
Diseases:Fuchs Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025
Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025
Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD)
Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Sets
CARLSBAD, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced its third quarter 2024 financial results and reviewed anticipated upcoming program milestones for its portfolio of GeneTACTM candidates.
“Thanks to our progress so far this year, the first half of 2025 will be a busy one, with data expected from our ongoing Phase 1 trial in FECD and the start of clinical activities for our FA program,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “We believe these programs lead a pipeline of GeneTACTM small molecules capable of transforming the status quo in genomic medicines, with the potential for multiple clinical proof-of-concept data sets over the next few years.”
Corporate Highlights and Anticipated Upcoming Milestones
- Friedreich Ataxia (FA)Design is on track to initiate the Phase 1 single ascending dose, normal healthy volunteer trial for DT-216P2 in the first half of 2025. The company anticipates beginning FA patient dosing later in 2025.
- Fuchs Endothelial Corneal Dystrophy (FECD)The company has initiated Phase 1 development for DT-168 in normal healthy volunteers, with initial data expected in the first half of 2025. In parallel, Design continues its ongoing FECD observational study.
- Pipeline programsDesign also continues to advance preclinical characterization of several lead molecules toward the selection of development candidates for Huntington’s disease (HD) and myotonic dystrophy type-1 (DM1) in anticipation of future IND submissions.
Third Quarter 2024 Financial Results
- R&D Expenses:Research and development (R&D) expenses were $11.9 million for the quarter ended September 30, 2024.
- G&A Expenses:General and administrative (G&A) expenses were $4.4 million for the quarter ended September 30, 2024.
- Net Loss:Net loss was $13.0 million for the quarter ended September 30, 2024.
- Cash Position and Operating Runway:Cash, cash equivalents and marketable securities were $254.1 million as of September 30, 2024, which the company expects to fund its planned operating expenses into 2029.
About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTACTM gene targeted chimera small molecules. The company’s GeneTACTM molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTACTM small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Forward-Looking StatementsStatements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to projections from early-stage programs, nonclinical data and early-stage clinical data; the progression or completion of certain development activities, including the selection of development candidates; the initiation and progression of studies and clinical trials for DT-216P2 and DT-168 and the timing thereof; the expected timing for data readouts; Design’s pipeline, including the potential to have four programs with clinical proof-of-concept with Design’s current cash runway; Design's ability to advance the GeneTACTM platform; Design’s estimated cash runway and the sufficiency of its resources to support its planned operations; and the capabilities and potential advantages of Design’s pipeline of GeneTACTM molecules. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “designed to,” “anticipates,” “capable of,” “on track to,” “plans to,” “expects,” “estimate,” “intends,” “will,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Design’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the acceptance of INDs by the FDA or similar applications by foreign regulatory agencies for the conduct of planned clinical trials of our product candidates and our proposed design of future clinical trials; nonclinical development activities and results of nonclinical studies; conducting a clinical trial and patient enrollment, which are affected by many factors, and any difficulties or delays encountered with such clinical trial or patient enrollment may delay or otherwise adversely affect Design’s clinical development plans; the process of discovering and developing therapies that are safe and effective for use as human therapeutics and operating as a development stage company; undesirable side effects or other undesirable properties, which could cause Design or regulatory authorities to suspend or discontinue clinical trials and thereby delay or prevent Design’s product candidates’ development or regulatory approval; Design’s ability to develop, initiate or complete nonclinical studies and clinical trials for its product candidates; whether promising early research or clinical trials will demonstrate safety and/or efficacy in later nonclinical studies or clinical trials; changes in Design’s plans to develop its product candidates; reliance on third parties to successfully conduct clinical trials and nonclinical studies; competitive products, which may make any products we develop or seek to develop obsolete or noncompetitive; Design’s reliance on key third parties, including contract manufacturers and contract research organizations; Design’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Design’s ability to obtain and maintain intellectual property protection for its product candidates; Design’s ability to recruit and retain key scientific or management personnel; and market conditions. For a more detailed discussion of these and other factors, please refer to Design’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of Design’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as filed with the SEC on August 5, 2024, and under the “Risk Factors” heading of Design’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Design undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Contact:Renee LeckTHRUST Strategic Communicationsrenee@thrustsc.com
| DESIGN THERAPEUTICS, INC.CONDENSED STATEMENTS OF OPERATIONS(in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| (unaudited) | |||||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 11,876 | $ | 13,257 | $ | 32,193 | $ | 46,051 | |||||||
| General and administrative | 4,370 | 5,565 | 13,496 | 17,018 | |||||||||||
| Total operating expenses | 16,246 | 18,822 | 45,689 | 63,069 | |||||||||||
| Loss from operations | (16,246 | ) | (18,822 | ) | (45,689 | ) | (63,069 | ) | |||||||
| Other income, net | 3,207 | 3,033 | 9,752 | 8,049 | |||||||||||
| Net loss | $ | (13,039 | ) | $ | (15,789 | ) | $ | (35,937 | ) | $ | (55,020 | ) | |||
| Net loss per share, basic and diluted | $ | (0.23 | ) | $ | (0.28 | ) | $ | (0.64 | ) | $ | (0.98 | ) | |||
| Weighted-average shares of common stock outstanding, basic and diluted | 56,620,731 | 55,988,691 | 56,555,312 | 55,948,867 | |||||||||||
| DESIGN THERAPEUTICS, INC.CONDENSED BALANCE SHEETS(in thousands) | |||||||
| September 30, | December 31, | ||||||
| 2024 | 2023 | ||||||
| (unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash, cash equivalents and investment securities | $ | 254,074 | $ | 281,798 | |||
| Prepaid expenses and other current assets | 3,168 | 2,786 | |||||
| Total current assets | 257,242 | 284,584 | |||||
| Property and equipment, net | 1,559 | 1,691 | |||||
| Right-of-use asset, related party | 2,401 | 2,938 | |||||
| Other assets | 427 | 430 | |||||
| Total assets | $ | 261,629 | $ | 289,643 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,470 | $ | 1,940 | |||
| Accrued expenses and other current liabilities | 5,962 | 7,682 | |||||
| Total current liabilities | 7,432 | 9,622 | |||||
| Operating lease liability, net, related party | 1,744 | 2,334 | |||||
| Total liabilities | 9,176 | 11,956 | |||||
| Total stockholders’ equity | 252,453 | 277,687 | |||||
| Total liabilities and stockholders’ equity | $ | 261,629 | $ | 289,643 | |||
